Comparative Pharmacology
Head-to-head clinical analysis: DEXACORT versus FLUDROCORTISONE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXACORT versus FLUDROCORTISONE ACETATE.
DEXACORT vs FLUDROCORTISONE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a glucocorticoid receptor agonist that modulates gene expression to produce anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Mineralocorticoid receptor agonist; promotes sodium reabsorption and potassium excretion in renal distal tubules, increasing extracellular fluid volume. Also has glucocorticoid activity.
Oral: 0.75-9 mg/day in divided doses; IV: 0.5-9 mg/day every 6-12 hours; IM: 4-20 mg every 2 weeks.
0.1 mg orally once daily, range 0.05-0.2 mg/day
None Documented
None Documented
Plasma terminal elimination half-life is 2.8-3.5 hours in adults, but the biological half-life (duration of HPA axis suppression) is 24-36 hours due to prolonged receptor occupancy
Terminal elimination half-life is 3.5 hours (range 2–5 h); clinical effect duration exceeds half-life due to mineralocorticoid receptor binding.
Renal (approximately 80% as inactive metabolites, <5% unchanged), biliary/fecal (minor, approximately 15-20%)
Renal (80%) as inactive metabolites; less than 5% unchanged; minor biliary/fecal elimination.
Category C
Category D/X
Corticosteroid
Corticosteroid